Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TQ05310 |
Synonyms | |
Therapy Description |
TQ05310 inhibits IDH2, potentially resulting in increased differentiation and decreased proliferation of tumor cells (PMID: 31361380). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TQ05310 | IDH2 Inhibitor 5 | TQ05310 inhibits IDH2, potentially resulting in increased differentiation and decreased proliferation of tumor cells (PMID: 31361380). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH2 R140Q | high grade glioma | sensitive | TQ05310 | Preclinical - Cell culture | Actionable | In a preclinical study, TQ05310 treatment decreased 2-HG levels and increased differentiation in a glioma cell line expressing IDH2 R140Q in culture (PMID: 31361380). | 31361380 |
IDH2 R140Q | acute myeloid leukemia | sensitive | TQ05310 | Preclinical - Cell culture | Actionable | In a preclinical study, TQ05310 treatment decreased 2-HG levels and increased differentiation in an acute myeloid leukemia cell line expressing IDH2 R140Q in culture (PMID: 31361380). | 31361380 |
IDH2 R172K | high grade glioma | sensitive | TQ05310 | Preclinical - Cell culture | Actionable | In a preclinical study, TQ05310 treatment decreased 2-HG levels and increased differentiation in a glioma cell line expressing IDH2 R172K in culture (PMID: 31361380). | 31361380 |
IDH2 R172K | acute myeloid leukemia | sensitive | TQ05310 | Preclinical - Cell culture | Actionable | In a preclinical study, TQ05310 treatment decreased 2-HG levels and increased differentiation in an acute myeloid leukemia cell line expressing IDH2 R172K in culture (PMID: 31361380). | 31361380 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|